Cationic Lipid Synthesis Route for Higher HEDC Yield and Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing synthetic processes for cationic lipids like 2-(bis(2-(tetradecanoyloxy)ethyl)amino)-N-(2-hydroxyethyl)-N,N-dimethyl-2-oxoethan-aminium bromide (HEDC) suffer from low yield, inconvenient work-up procedures, and high side product formation, necessitating a more efficient and accessible synthesis method.
Innovation Solution
A multi-step process involving the reaction of compounds of Formula II, III, and IV with methanesulfonic acid, followed by oxalic acid and bromoethanol under controlled conditions, to produce HEDC with improved yield and purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If previous synthetic strategies for producing HEDC are used, then the synthesis can be completed, but the yield is low and there are high side product formations
Solution Approach 1:
The synthesis process is divided into three distinct steps: (1) formation of intermediate compound of Formula IV from compounds of Formula II and III, (2) formation of intermediate compound of Formula VI from compound of Formula IV and compound of Formula V, and (3) formation of final HEDC product from compound of Formula VI and bromoethanol. This segmentation allows each step to be optimized independently, achieving at least 60% yield in each step and overall yield of at least 36%, while minimizing side products through controlled conditions at each stage.
Solution Approach 2:
The patent employs specific parameter changes including controlled temperature conditions, selection of appropriate solvents, and optimization of reagent equivalents (bromoethanol used in between about 2 and about 4 equivalents). These parameter adjustments ensure high purity product with minimal side products while maintaining good yield throughout the multi-step synthesis process.
2Productivity
If previous synthetic strategies for producing HEDC are used, then the synthesis can be completed, but the work-up procedures are inconvenient
Solution Approach 1:
The patent simplifies work-up procedures by extracting and removing side products at each step through controlled purification methods. The intermediate compounds are isolated as solids or crystalline solids with high purity, eliminating the need for complex chromatographic purification procedures and making the overall process more convenient and scalable.
3Reliability
If cationic lipids of formula I are used, then superior reduction in protein expression is achieved, but the synthesis complexity increases
Solution Approach 1:
The patent employs preliminary action by synthesizing and isolating intermediate compounds (Formula IV and Formula VI) as solid or crystalline solids with high purity before forming the final HEDC product. This preliminary purification eliminates the need for complex chromatographic procedures later, simplifying the overall synthesis process while ensuring the final product has the desired transfection efficiency and protein expression reduction properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves yields of at least 60% for HEDC with high purity, reducing the need for chromatographic purification and minimizing by-products, thus enhancing the efficiency and accessibility of cationic lipid synthesis.
Implementation Method 1
reacting a compound of Formula II with a compound of Formula III and methanesulfonic acid to form a compound of Formula IV
Implementation Method 2
reacting a compound of Formula IV with a compound of Formula V and oxalic acid to form a compound of Formula VI
Implementation Method 3
reacting a compound of Formula VI with bromoethanol under coupling conditions to form a compound of Formula I
Data Source
AI summary
The present application provides processes for synthesizing cationic lipids of Formula I useful in the synthesis of fat-soluble compositions for targeting and enhancing activity of therapeutic molecules, including siRNA.